REC 0545

Drug Profile

REC 0545

Latest Information Update: 13 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Assistance Publique Hopitaux de Paris; Recordati
  • Class Amino acids
  • Mechanism of Action Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Maple syrup urine disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Maple syrup urine disease
  • Discontinued Genitourinary disorders; Overactive bladder

Most Recent Events

  • 05 Nov 2018 REC 0545 receives Orphan Drug status for Maple syrup urine disease in European Union
  • 01 Mar 2018 Recordati and Assistance Publique Hopitaux de Paris plans a clinical trial for Maple syrup urine disease (Recordati pipeline, February 2018)
  • 31 Dec 2007 Discontinued - Phase-II for Overactive bladder in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top